← Human Trials & Peer-Reviewed Studies
Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease.
Plain-language guide to PMID 33037656 (2021): pilot randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), fatty liver & elevated liver enzymes.
Key Facts
- PMID
- 33037656
- Journal
- Clinical endocrinology
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Pan CS et al. (9 authors)
- DOI
- 10.1111/cen.14344
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the context of fatty liver & elevated liver enzymes, published as a randomized controlled trial.
The effects of GH on NAFLD in those with obesity are unknown, however, prompting this pilot study to assess effects of GH administration on measures of NAFLD in young adults.
Why It Was Studied
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in young adults with obesity.
Who Took Part
By PubMed's age tags, the people studied were young adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized and pilot study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.
The primary endpoint was change in HFF.
What Was Measured
The subject headings attached to it are Dwarfism, Pituitary, Growth Hormone, Human Growth Hormone, Insulin-Like Growth Factor I, Non-alcoholic Fatty Liver Disease and Pilot Projects.
The authors tagged it with the keywords conditions: obesity/lipids/nutrition, hormones/related: pituitary, nonalcoholic fatty liver disease and obesity.
What This Means in Plain Language
The paper is a randomized and pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in people with fatty liver & elevated liver enzymes.
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2021 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, Fatty liver & elevated liver enzymes research.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
- Fatty liver & elevated liver enzymes research
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.